Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
Federico Ravaioli, Elton Dajti, Alessandro Mantovani, et al.
Gut (2023) Vol. 72, Iss. 7, pp. 1399-1409
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 47
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani, et al.
Metabolites (2024) Vol. 14, Iss. 1, pp. 40-40
Open Access | Times Cited: 12
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
Laurent Castéra, Philippe Garteiser, Cédric Laouénan, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 195-206
Closed Access | Times Cited: 11
Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet
Roberta Rinaldi, Sara De Nucci, Rossella Donghia, et al.
Nutrients (2024) Vol. 16, Iss. 10, pp. 1408-1408
Open Access | Times Cited: 10
Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
Laura Valenzuela‐Vallejo, Despina Sanoudou, Christos S. Mantzoros
Journal of Personalized Medicine (2023) Vol. 13, Iss. 5, pp. 830-830
Open Access | Times Cited: 16
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, et al.
Liver International (2024) Vol. 44, Iss. 5, pp. 1129-1141
Closed Access | Times Cited: 5
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
Andrea Dalbeni, Rosa Lombardi, M. K. Costa Luís Henrique, et al.
Hepatology (2023) Vol. 79, Iss. 5, pp. 1107-1116
Closed Access | Times Cited: 13
Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study
Samuel J. Daniels, Karin Nelander, John Eriksson, et al.
Contemporary Clinical Trials Communications (2025) Vol. 44, pp. 101437-101437
Open Access
Attenuation imaging: Diagnostic differences in hepatic steatosis for chronic hepatitis B vs metabolic dysfunction-associated steatotic liver disease patients
Xueqi Li, Cheng Guang-wen, Iwaki Akiyama, et al.
World Journal of Gastroenterology (2025) Vol. 31, Iss. 11
Closed Access
FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial
Vincent Wai‐Sun Wong, Quentin M. Anstee, Louise Maymann Nitze, et al.
EClinicalMedicine (2023) Vol. 66, pp. 102310-102310
Open Access | Times Cited: 10
FAST and Agile–the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin
Mădălina-Gabriela Țâru, Cristian Tefas, Lidia Neamți, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0303971-e0303971
Open Access | Times Cited: 3
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests
Jesse Fishman, Thomas O’Connell, Christina M. Parrinello, et al.
Journal of health economics and outcomes research (2024), pp. 32-43
Open Access | Times Cited: 2
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests
Jesse Fishman, Thomas O’Connell, Christina M. Parrinello, et al.
Journal of health economics and outcomes research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 2
FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis
Jingya Yin, Tianyuan Yang, Bingqing Yang, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 18, pp. 2440-2453
Open Access | Times Cited: 2
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Wah‐Kheong Chan, Salvatore Petta, Mazen Noureddin, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 2
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Yue Wang, Sherlot Juan Song, Yichong Jiang, et al.
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 2
acFibroMASH index for the diagnosis of fibrotic MASH and prediction of liver-related events: An international multicenter study
Gong Feng, Ferenc E. Mózes, Dong Ji, et al.
Clinical Gastroenterology and Hepatology (2024)
Closed Access | Times Cited: 2
Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
Juan Macı́as, Mario Frías, Juan A. Pineda, et al.
Alimentary Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 2
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
Angelo Armandi, Maurice Stephan Michel, Kamela Gjini, et al.
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 9, pp. 771-782
Closed Access | Times Cited: 5
Metabolic dysfunction associated steatotic liver disease—Clinicians should not underestimate the role of steatosis
Johannes Wiegand, David Petroff, Thomas Karlas
United European Gastroenterology Journal (2024) Vol. 12, Iss. 3, pp. 277-278
Open Access | Times Cited: 1
Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease: Detecting Advanced Fibrosis based on Reported Liver Stiffness Measurement in FibroScan and Laboratory Findings
Mohammadjavad Sotoudeheian
The International Journal of Gastroenterology and Hepatology Diseases (2024) Vol. 03
Closed Access | Times Cited: 1
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
Chi‐Ho Lee, David Tak Wai Lui, Lung‐Yi Mak, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 574-582
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top